Importantly, initiation of GLP-1RA may decrease levothyroxine dose requirements in patients with hypothyroidism through weight loss, enhance levothyroxine absorption due to delayed gastrointestinal (GI) transit, and have direct effects on the hypothalamic-pituitary-thyroid axis [23,24,25,26,27,28,29], potentially increasing the risk of thyroid hormone over-replacement (i.e., iatrogenic hyperthyroidism)
You can read my full thoughts on Unicity Balance here
Semaglutide and other GLP-1 medications trigger nausea in roughly 25-40% of users, especially after meals, because they mimic a natural gut hormone that slows digestion and reduces appetite
Ngi dng c th ghi li ngy bt u trn giy hoc trong ng dng nhc nh d dng theo di v quyt nh thi im dng hoc tip tc vi hp tip theo
405 RossiM.CarusoF.AntoniolettiR.VigliantiA.TraversiG.LeoneS.et al (2013)